Ignite Creation Date:
2024-05-05 @ 4:54 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00330551
Status:
COMPLETED
Last Update Posted:
2023-03-01
First Post:
2006-05-26
Brief Title:
Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia
Sponsor:
University of California Los Angeles
Organization:
University of California Los Angeles
Organization Data
Organization:
University of California Los Angeles
Class:
OTHER
Study ID:
P50MH066286
Study Type:
NIH
Study Domain:
None
Study Link:
httpsreporternihgovquickSearchP50MH066286
Lead Sponsor:
University of California Los Angeles
Lead Sponsor Class:
OTHER
Responsible Party:
Keith Nuechterlein PhD
Responsible Party Title:
Professor University of California Los Angeles
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
University of California Los Angeles
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Janssen Scientific Affairs LLC | INDUSTRY |
| National Institute of Mental Health NIMH | NIH |